BeOne Medicines (688235.SS) Stock Price

BeOne Medicines Price

SSE·CLOSED
289.64CNY-4.14 (-1.42 %)
Market closed

Revenue has compounded at 65.8% per year over the past 6 years to 27.21 B CNY. BeOne Medicines's net margin stands at -18.3%, up from -536.9% several years earlier. Analysts set a median price target of 370.68 CNY, implying 28.0% above the current price. Of 15 analysts, 14 rate the stock a buy — an overall Buy consensus. The stock trades about 39% above its 52-week low.

BeOne Medicines stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of BeOne Medicines over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how BeOne Medicines stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing BeOne Medicines's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

BeOne Medicines Stock Price History
DateBeOne Medicines Price
8/19/2026289.64 CNY
8/18/2026293.78 CNY
8/17/2026289.52 CNY
8/14/2026287.71 CNY
8/13/2026292.18 CNY
8/12/2026301.88 CNY
8/11/2026300.30 CNY
8/10/2026297.29 CNY
8/7/2026299.33 CNY
8/6/2026269.00 CNY
8/5/2026270.36 CNY
8/4/2026261.96 CNY
8/3/2026249.65 CNY
7/31/2026261.20 CNY
7/30/2026259.51 CNY
7/29/2026269.21 CNY
7/28/2026263.18 CNY
7/27/2026274.00 CNY
7/24/2026271.00 CNY
7/23/2026270.68 CNY
7/22/2026277.29 CNY
7/21/2026275.50 CNY
7/20/2026258.46 CNY
7/17/2026250.51 CNY
7/16/2026271.73 CNY
7/15/2026274.51 CNY
7/14/2026269.00 CNY
7/13/2026256.54 CNY
7/10/2026267.84 CNY
7/9/2026260.78 CNY
7/8/2026256.62 CNY
7/7/2026263.16 CNY
7/6/2026277.00 CNY
7/3/2026265.40 CNY
7/2/2026253.56 CNY
7/1/2026261.80 CNY
6/30/2026254.61 CNY
6/29/2026255.90 CNY
6/26/2026232.10 CNY
6/25/2026242.71 CNY
6/24/2026236.79 CNY
6/23/2026228.00 CNY
6/22/2026216.54 CNY
6/18/2026218.81 CNY
6/17/2026211.45 CNY
6/16/2026214.57 CNY
6/15/2026214.34 CNY
6/12/2026211.00 CNY
6/11/2026208.40 CNY
6/10/2026213.34 CNY
6/9/2026213.90 CNY
6/8/2026214.57 CNY
6/5/2026220.18 CNY
6/4/2026223.98 CNY
6/3/2026222.41 CNY
6/2/2026220.82 CNY
6/1/2026234.62 CNY
5/29/2026243.90 CNY
5/28/2026233.25 CNY
5/27/2026239.38 CNY
5/26/2026244.08 CNY
5/25/2026241.71 CNY
5/22/2026244.57 CNY
5/21/2026251.96 CNY
5/20/2026243.98 CNY
5/19/2026239.97 CNY
5/18/2026239.20 CNY
5/15/2026252.02 CNY
5/14/2026249.70 CNY
5/13/2026260.80 CNY
5/12/2026267.98 CNY
5/11/2026262.08 CNY
5/8/2026247.50 CNY
5/7/2026254.40 CNY
5/6/2026246.86 CNY
4/30/2026234.80 CNY
4/29/2026236.31 CNY
4/28/2026233.01 CNY
4/27/2026235.00 CNY
4/24/2026234.86 CNY
4/23/2026234.32 CNY
4/22/2026241.19 CNY
4/21/2026240.10 CNY
4/20/2026245.20 CNY
4/17/2026246.50 CNY
4/16/2026256.99 CNY
4/15/2026254.40 CNY
4/14/2026242.07 CNY
4/13/2026241.95 CNY
4/10/2026244.12 CNY
4/9/2026242.56 CNY
4/8/2026245.88 CNY
4/7/2026237.12 CNY
4/3/2026239.29 CNY
4/2/2026249.25 CNY
4/1/2026249.90 CNY
3/31/2026233.59 CNY
3/30/2026235.30 CNY
3/27/2026232.69 CNY
3/26/2026216.49 CNY
3/25/2026220.17 CNY
3/24/2026221.11 CNY
3/23/2026215.51 CNY
3/20/2026227.57 CNY
3/19/2026235.00 CNY
3/18/2026238.50 CNY
3/17/2026236.74 CNY
3/16/2026231.30 CNY
3/13/2026228.68 CNY
3/12/2026233.84 CNY
3/11/2026238.09 CNY
3/10/2026245.20 CNY
3/9/2026232.89 CNY
3/6/2026238.28 CNY
3/5/2026237.00 CNY
2/27/2026257.50 CNY
2/26/2026263.78 CNY
2/25/2026279.58 CNY
2/13/2026279.64 CNY
2/12/2026282.70 CNY
2/11/2026286.91 CNY
2/10/2026286.02 CNY
2/9/2026276.75 CNY
2/6/2026272.84 CNY
2/5/2026275.61 CNY
2/4/2026277.92 CNY
2/3/2026273.39 CNY
2/2/2026269.21 CNY
1/30/2026277.99 CNY
1/29/2026285.84 CNY
1/28/2026288.92 CNY
1/27/2026285.99 CNY
1/26/2026285.10 CNY
1/23/2026289.21 CNY
1/22/2026287.80 CNY
1/21/2026292.34 CNY
1/20/2026287.28 CNY
1/19/2026294.40 CNY
1/16/2026306.30 CNY
1/15/2026307.00 CNY
1/14/2026308.15 CNY
1/13/2026311.17 CNY
1/12/2026312.77 CNY
1/9/2026312.50 CNY
1/8/2026307.72 CNY
1/7/2026307.92 CNY
1/6/2026298.76 CNY
1/5/2026300.60 CNY
12/31/2025268.61 CNY
12/30/2025272.18 CNY
12/29/2025274.20 CNY
12/26/2025275.30 CNY
12/25/2025273.30 CNY
12/24/2025277.93 CNY
12/23/2025276.70 CNY
12/22/2025274.10 CNY
12/19/2025273.70 CNY
12/18/2025271.66 CNY
12/17/2025271.30 CNY
12/15/2025270.65 CNY
12/12/2025276.48 CNY
12/11/2025274.62 CNY
12/10/2025276.87 CNY
12/8/2025279.54 CNY
12/5/2025279.26 CNY
12/4/2025280.20 CNY
12/3/2025275.20 CNY
12/2/2025279.65 CNY
12/1/2025287.66 CNY
11/28/2025289.58 CNY
11/27/2025286.68 CNY
11/26/2025285.72 CNY
11/25/2025283.45 CNY
11/24/2025285.41 CNY
11/21/2025279.00 CNY
11/20/2025283.33 CNY
11/19/2025284.02 CNY
11/18/2025289.38 CNY
11/17/2025290.80 CNY
11/14/2025298.80 CNY
11/13/2025304.51 CNY
11/12/2025293.45 CNY
11/11/2025278.75 CNY
11/10/2025280.20 CNY
11/7/2025279.02 CNY
11/6/2025277.29 CNY
11/5/2025270.24 CNY
11/4/2025272.59 CNY
11/3/2025282.57 CNY
10/31/2025296.75 CNY
10/30/2025281.71 CNY
10/29/2025289.18 CNY
10/28/2025285.00 CNY
10/27/2025288.04 CNY
10/24/2025279.80 CNY
10/23/2025276.36 CNY
10/22/2025281.60 CNY
10/21/2025282.55 CNY
10/20/2025274.55 CNY
10/17/2025273.67 CNY
10/16/2025285.67 CNY
10/15/2025281.56 CNY
10/14/2025273.71 CNY
10/13/2025284.27 CNY
10/10/2025285.50 CNY
10/9/2025304.50 CNY
9/30/2025306.98 CNY
9/29/2025301.02 CNY
9/26/2025301.85 CNY
9/25/2025315.67 CNY
9/24/2025309.70 CNY
9/23/2025303.56 CNY
9/22/2025314.50 CNY
9/19/2025307.97 CNY
9/18/2025315.00 CNY
9/17/2025313.47 CNY
9/16/2025316.86 CNY
9/15/2025319.80 CNY
9/12/2025315.64 CNY
9/11/2025305.18 CNY
9/10/2025316.99 CNY
9/9/2025323.20 CNY
9/8/2025317.95 CNY
9/5/2025319.03 CNY
9/4/2025308.00 CNY
9/3/2025324.44 CNY
9/2/2025324.80 CNY
9/1/2025300.00 CNY
8/29/2025278.04 CNY
8/28/2025246.86 CNY
8/27/2025246.39 CNY
8/26/2025250.51 CNY
8/25/2025254.99 CNY
8/22/2025247.24 CNY
8/21/2025243.29 CNY
Access this data via the Eulerpool API
Get Free API Key

BeOne Medicines Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
9.57 B CNY
-12.03 B CNY
-13.64 B CNY
Jan 1, 2023
17.42 B CNY
-8.75 B CNY
-6.72 B CNY
Jan 1, 2024
27.21 B CNY
-4.24 B CNY
-4.98 B CNY
Jan 1, 2025 (e)
35.84 B CNY
-18.29 B CNY
2.19 B CNY
Jan 1, 2026 (e)
44.37 B CNY
-22.65 B CNY
5.04 B CNY
Jan 1, 2027 (e)
51.35 B CNY
-26.21 B CNY
6.89 B CNY
Jan 1, 2028 (e)
58.57 B CNY
-29.89 B CNY
9.31 B CNY
Jan 1, 2029 (e)
64.91 B CNY
-33.13 B CNY
11.24 B CNY

BeOne Medicines Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 21, 2026, 4:11 AM
 
REVENUEB CNY
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB CNY
EBITB CNY
EBIT MARGIN%
NET INCOMEB CNY
NET INCOME GROWTH%
SHARESB
20182019202020212022202320242025e2026e2027e2028e2029e2030e2031e
1.312.952.127.599.5717.4227.2135.8444.3751.3558.5764.9173.5374.89
–125.50-28.23257.9226.0782.1356.2031.7023.8015.7314.0510.8313.281.85
85.5083.3477.0886.0280.1184.4584.3384.3384.3384.3384.3384.3384.3384.33
1.122.461.636.537.6614.7122.9530.2237.4243.3149.3954.7462.0163.15
-4.83-6.80-11.36-9.47-12.03-8.75-4.24-18.29-22.65-26.21-29.89-33.13-37.53–
-368.78-230.06-535.94-124.78-125.71-50.22-15.58-51.04-51.04-51.04-51.04-51.04-51.04–
-4.75-6.91-11.38-9.75-13.64-6.72-4.982.195.046.899.3111.2413.79177.87
–45.6864.64-14.3739.96-50.78-25.87-143.99130.0036.8335.0620.7122.741,189.73
1.331.331.331.331.341.361.371.371.371.371.371.371.371.37
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales BeOne Medicines generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue BeOne Medicines retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare BeOne Medicines's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares BeOne Medicines has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against BeOne Medicines's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

BeOne Medicines stock margins

The BeOne Medicines margin analysis displays the gross margin, EBIT margin, as well as the profit margin of BeOne Medicines. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for BeOne Medicines.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
77.09 %
-535.92 %
-536.92 %
Jan 1, 2021
86.02 %
-124.77 %
-128.45 %
Jan 1, 2022
80.10 %
-125.71 %
-142.60 %
Jan 1, 2023
84.45 %
-50.22 %
-38.55 %
Jan 1, 2024
84.33 %
-15.59 %
-18.29 %
Jan 1, 2025 (e)
84.33 %
-51.04 %
6.11 %
Jan 1, 2026 (e)
84.33 %
-51.04 %
11.35 %
Jan 1, 2027 (e)
84.33 %
-51.04 %
13.42 %

BeOne Medicines Stock Revenue, EBIT, Earnings per Share

The BeOne Medicines earnings per share therefore indicates how much revenue BeOne Medicines has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
1.59 CNY
-8.51 CNY
-8.53 CNY
Jan 1, 2021
5.69 CNY
-7.09 CNY
-7.30 CNY
Jan 1, 2022
7.14 CNY
-8.97 CNY
-10.18 CNY
Jan 1, 2023
12.84 CNY
-6.45 CNY
-4.95 CNY
Jan 1, 2024
19.90 CNY
-3.10 CNY
-3.64 CNY
Jan 1, 2025 (e)
26.21 CNY
-13.38 CNY
1.60 CNY
Jan 1, 2026 (e)
32.44 CNY
-16.56 CNY
3.68 CNY
Jan 1, 2027 (e)
37.55 CNY
-19.16 CNY
5.04 CNY

BeOne Medicines business model & stock analysis

BeOne Medicines Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

BeOne Medicines historical P/E ratio, EBIT multiple, and P/S ratio

BeOne Medicines annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

BeOne Medicines shares outstanding

The number of shares of BeOne Medicines was 1.37 B in 2025. This indicates how many shares BeOne Medicines is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
1.33 B Stocks
Jan 1, 2021
1.33 B Stocks
Jan 1, 2022
1.34 B Stocks
Jan 1, 2023
1.36 B Stocks
Jan 1, 2024
1.37 B Stocks
Jan 1, 2025 (e)
1.37 B Stocks
Jan 1, 2026 (e)
1.37 B Stocks
Jan 1, 2027 (e)
1.37 B Stocks

Current BeOne Medicines forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
2.59 %
Buy
93.33 % (14)
Hold
6.67 % (1)
Sell
0.00 % (0)
12M Price Target
370.68
Last Price
289.64
Currency
CNY
12M Return Potential
27.98 %
LTM Return
0 %

BeOne Medicines Analyst Rating Actions

DateFirmActionRatingReliability
9/20/2023
Citigroup
Citigroup
MaintainedBuy41
9/19/2023
B of A Securities
B of A Securities
MaintainedNeutral68
8/28/2023
Morgan Stanley
Morgan Stanley
MaintainedOverweight48
8/6/2023
JP Morgan
JP Morgan
MaintainedOverweight62
6/29/2023
Bernstein
Bernstein
DowngradeOutperformMarket Perform48
4/11/2023
B of A Securities
B of A Securities
MaintainedNeutral68
2/28/2023
Guggenheim
Guggenheim
MaintainedBuy30
2/27/2023
Morgan Stanley
Morgan Stanley
MaintainedOverweight48
2/27/2023
Cowen & Co.
Cowen & Co.
MaintainedOutperform60
1/23/2023
Morgan Stanley
Morgan Stanley
MaintainedOverweight48

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

BeOne Medicines Earnings Calls

2025

BeOne Medicines Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
2/26/2024-0.60CNY-4.37 BCNY-2023 Q4
2/23/2023-0.45CNY-2.62 BCNY-2022 Q4
11/9/2022-2.82CNY-2.42 BCNY-2022 Q3
8/4/2022-2.22CNY-2.06 BCNY-2022 Q2
5/5/2022-1.91CNY-1.85 BCNY-2022 Q1
2/25/2022-2.55CNY-1.42 BCNY-2021 Q4

EESG©

Eulerpool ESG Scorecard© for the BeOne Medicines stock

76/100
75
Environment
99
Social
54
Governance
E

Environment

20
Scope 1 - Direct Emissions3,547
Scope 2 - Indirect emissions from purchased energy81,095
Scope 3 - Indirect emissions within the value chain662,688
Total CO₂ emissions84,642
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees58.2
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

BeOne Medicines shareholder structure

% Name
0.03650%
Ninety One UK Limited
Ninety One UK Limited
0.02494%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
0.00687%
State Street Global Advisors (UK) Ltd.
State Street Global Advisors (UK) Ltd.
0.00529%
Eurizon Capital (HK) Limited
Eurizon Capital (HK) Limited
0.00506%
BlackRock Investment Management (UK) Ltd.
BlackRock Investment Management (UK) Ltd.
0.00477%
State Street Global Advisors (US)
State Street Global Advisors (US)

BeOne Medicines Beneficial Ownership Filings (SEC 13D/G)

Free Float
84.4%
Float Shares
-
Shares Outstanding
-

BeOne Medicines Executives and Management Board

17 members · avg. age 57 · 18 % women

JO

Mr. John Oyler (56)

Co-Founder, Executive Chairman of the Board, Chief Executive Officer · since 2010

16.74 M CNY

Management

XW

Dr. Xiaobin Wu (62)

President, Chief Operating Officer, General Manager - China

–
AR

MR. Aaron Rosenberg (48)

Chief Financial Officer · since 2024

–
CL

Mr. Chan Lee (56)

Senior Vice President, General Counsel

–
GB

Mr. Giancarlo Benelli

Senior Vice President, Head of Europe

–
MS

Mr. Matthew Shaulis (51)

General Manager, North America

–
LW

Dr. Lai Wang (47)

Global Head of R&D

–

Board of Directors

XW

Dr. Xiaodong Wang (61)

Co-Founder, Non-Executive Director

4.27 M CNY
AH

Mr. Anthony Hooper (69)

Non-Executive Independent Director

518,000.00 CNY
HD

Dr. Han Dugan (67)

Non-Executive Independent Director

516,000.00 CNY
CS

Dr. Corazon Sanders (67)

Non-Executive Independent Director

507,000.00 CNY
AR

Dr. Alessandro Riva (63)

Non-Executive Independent Director

497,000.00 CNY
RK

Mr. Ranjeev Krishana (50)

Lead Non-Executive Independent Director

492,000.00 CNY

BeOne Medicines Supply Chain

BeOne Medicines Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
27 companies
#NameTrend
1
Mirati Therapeutics
Supplier·Customer·Biotechnology·US
0.84
0.11
0.84
—
—
—
2
PureTech Health
Customer·Biotechnology·US
0.79
-0.37
0.72
—
—
—
3
Sinopharm Group H
Customer·Health Care Providers & Services·CN
0.77
-0.20
0.32
—
—
—
4
Zymeworks
Supplier·Customer·Biotechnology·CA
0.65
0.46
0.46
—
—
—
5
IGM Biosciences
Supplier·Customer·Biotechnology·US
0.61
0.06
0.12
—
—
—

Frequently asked questions about BeOne Medicines

Analysts currently set an average price target of 369.28 CNY for the BeOne Medicines stock (median: 370.68 CNY), implying +27.5 % versus the latest price. The consensus is based on 15 analyst ratings.

BeOne Medicines Analyst Price Targets 2026

15 analysts currently rate the BeOne Medicines stock: 14 recommend buying, 1 holding and 0 selling. For 2026, analysts expect BeOne Medicines to generate revenue of 44.37 B CNY and earnings per share of 3.68 CNY.

BeOne Medicines Analyst Price Targets 2026

Converted at the current exchange rate, the BeOne Medicines share trades at 36.81 EUR (289.64 CNY).

No history available for BeOne Medicines.

The expected revenue of BeOne Medicines is 44.37 B CNY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of BeOne Medicines is 5.04 B CNY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of BeOne Medicines is currently 78.63. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the BeOne Medicines stock.

The price-to-sales ratio (P/S) of BeOne Medicines is currently 8.93. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the BeOne Medicines stock.

The Eulerpool Quality Score for BeOne Medicines is 3/10.

The ISIN of BeOne Medicines is CNE100005XT6. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of BeOne Medicines is 688235.SS. The ticker symbol is used to trade BeOne Medicines shares on the stock exchange.

BeOne Medicines paid dividends every year for the past 0 years.

BeOne Medicines is assigned to the 'Health' sector.

The dividends of BeOne Medicines are distributed in CNY.

All fundamentals and in-depth analysis of BeOne Medicines

Our stock analysis for BeOne Medicines stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BeOne Medicines. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

BeOne Medicines Stock
BeOne Medicines Revenue→
BeOne Medicines Stock
BeOne Medicines Net Income→
BeOne Medicines Stock
BeOne Medicines P/E→
BeOne Medicines Stock
BeOne Medicines P/S→
BeOne Medicines Stock
BeOne Medicines EBIT→
BeOne Medicines Stock
BeOne Medicines Dividend→
BeOne Medicines Stock
BeOne Medicines Directors Dealings→
BeOne Medicines Stock
BeOne Medicines Stocks→
BeOne Medicines Stock
BeOne Medicines Market capitalization→
BeOne Medicines Stock
BeOne Medicines Debt→
BeOne Medicines Stock
BeOne Medicines Liabilities→
BeOne Medicines Stock
BeOne Medicines Equity→
BeOne Medicines Stock
BeOne Medicines AAQS→
BeOne Medicines Stock
BeOne Medicines Employees→
BeOne Medicines Stock
BeOne Medicines ROE→
BeOne Medicines Stock
BeOne Medicines ROA→
BeOne Medicines Stock
BeOne Medicines ROCE→
BeOne Medicines Stock
BeOne Medicines News→
BeOne Medicines Stock
BeOne Medicines Analyst Price Targets→

Health Stocks

Berry Genomics CoBenQ Medical TechnologyBeryl DrugsBenitec BiopharmaBespoke ExtractsBen Tre Pharmaceutical JSCBeta BionicsBelite Bio Inc ADRBetta Pharmaceuticals CoBeijing Wantai Biological Pharmacy Enterprise CoBetter TherapeuticsBeijing Wandong Medical Technology CoAll Stocks A–Z →